HPPH

A photosentizer

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥712.00

570.00

- +
5mg

￥1775.00

1420.00

- +
10mg

￥2875.00

2300.00

- +
25mg

￥5700.00

4560.00

- +
50mg

￥8312.00

6650.00

- +
100mg

￥16950.00

13560.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajce50442
CAS: 149402-51-7
别名: 光克洛,Photochlor
分子式: C39H48N4O4
分子量: 636.82
纯度: >98%
溶解度: DMSO: 125 mg/mL (196.29 mM); Water: < 0.1 mg/mL (insoluble)
储存: 4°C, away from moisture and light
库存: 现货

Background

HPPH is a chlorin that acts as a photosensitizer in photodynamic therapy (PDT) when stimulated with light at 655 nm.¹ When administered systemically, HPPH accumulates in tumor cells and, when stimulated with light in the presence of oxygen, reactive oxygen species (ROS) are generated, leading to necrosis within the tumor. HPPH, at a dose of 0.5 mg/kg, increases survival in a nude rat model of glioma.² It works synergistically with gemcitabine in several pancreatic cancer cell lines to induce cell death.³

1.Dennis, E.J., Dolmans, G.J., Fukumura, D., et al.Photodynamic therapy for cancerNature31-8(2003) 2.Lobel, J., MacDonald, I.J., Ciesielski, M.J., et al.2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) in a nude rat glioma model: implications for photodynamic therapyLasers Surg. Med.29(5)397-405(2001) 3.Sun, G., Anderson, M.A., Gorospe, E.C., et al.Synergistic effects of photodynamic therapy with HPPH and gemcitabine in pancreatic cancer cell linesLasers Surg. Med.44(9)755-761(2012)

Protocol

Cell experiment:

4T1 cells are cultured in 96-well cell culture plates at 1×104/well for 24 h and then treated with GO-PEG-HPPH, HPPH, or GO-PEG at a series of concentrations (0.078125, 0.15625, 0.3125, 0.625, 1.25, 2.5, 5, 10, and 20 μM). Then, 20 μL of MTT solution (5.0 mg/mL) is added to each well. After the 4 h incubation with the MTT, the media are removed and 100 μL of DMSO is added to solubilize the formazan crystals. The cell toxicity efficacy is measured with a microplate reader at an absorbance of 570 nm[1].

Animal experiment:

Mice[2]Tumor-bearing mice are injected in the tail vein with 0.4 μmol/kg HPPH or 5 mg/kg Porfimer sodium (PII), followed 18-24 h later by illumination to a total light dose of 48 J/cm2 or 132 J/cm2 delivered at a light dose-rate of 14 mW/cm2. Control mice are treated with photosensitizer or light alone. Mice receiving a combination PDT regimen are treated initially with 0.4 μmol/kg HPPH or 5 mg/kg PII followed 18-24 h later by light dose of 48 J/cm2 given at 14 mW/cm2; 9 days later, mice are again injected with photosensitizer and tumors are illuminated with light at a dose of 132 J/cm2 given at 14 mW/cm2[2].

参考文献:

[1]. Rong P, et al. Photosensitizer loaded nano-graphene for multimodality imaging guided tumor photodynamic therapy. Theranostics. 2014 Jan 15;4(3):229-39.
[2]. Shams M, et al. Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease. Cancer Immunol Immunother. 2015 Mar;64(3):287-97.